Veracyte, Inc. (VCYT)
Veracyte sells diagnostic tests, many for cancer, to physicians and healthcare providers from South San Francisco, California. It last closed at $24.23 on Nov 17, up 0.92% on the day. The average 12-month price target from 6 analysts is $37.67 (+55.5% from the last close), with a high of $46.00 and a low of $30.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (5 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $518K, the largest $518K.
Key Stats
Last 12 monthsNot reported for this period.
From VCYT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 6 analysts who set a price target on VCYT in the past 90 days. The average target is $37.67, with a high of $46.00 and a low of $30.00, compared with the last close of $24.23.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 11 | Stephens & Co. | Target lowered | Buy | $55 → $40 |
| Nov 10 | Piper Sandler | Target lowered | Buy | $54 → $30 |
| Nov 10 | Freedom Capital Markets | Target lowered | Buy | $66 → $40 |
| Nov 9 | UBS | Target lowered | Buy | $65 → $35 |
| Nov 5 | Leerink Partners | Downgrade | Hold | $35 |
Technical Analysis
The stock is 58% below its 20 day and 71% below its 50 day average. It is 74% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot at $24.10, and the nearest resistance the Pivot R1 at $24.60.
| RSI (14) | 28.34 | Oversold below 30 | Oversold |
| MACD | -5.98 | Below its signal line | Bearish |
| Stochastic | 7.4 | Near the bottom of its range | Oversold |
| ADX (14) | 42.3 | Strong downtrend | |
| Williams %R | -92.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -76.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −51.8% | Change over 10 sessions | Bearish |
| ATR (14) | $3.19 | Typical daily range, 13.2% of price |
| RSI (14) | 32.64 | Weak, oversold below 30 | Neutral |
| MACD | -3.39 | Below its signal line | Bearish |
| Stochastic | 7.4 | Near the bottom of its range | Oversold |
| ADX (14) | 22.1 | Weak trend | |
| Williams %R | -92.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -218.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −40.7% | Change over 10 sessions | Bearish |
| ATR (14) | $6.43 | Typical daily range, 26.5% of price |
What happened before
See how VCYT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How VCYT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
Whale Options Flow
90DNo whale options trades in VCYT in the last 90 days.
Dark Pool
30DVCYT Institutional Ownership
Full report →- ▲248 buying vs 147 selling
- ▲Held by funds +6.2 pts
- ▲Funds holding +11
- ▼Superinvestors: 2 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 384 | 373 | +2.9% |
| In funds' top 10 | 2 | 1 | +100.0% |
| Held by funds | 117.3% | 111.1% | +6.2 pts |
| New / increased | 75 / 173 | 77 / 129 | +20.4% |
| Reduced / sold out | 86 / 61 | 121 / 41 | −9.3% |
| Put/call ratio | 0.91 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VCYT is in one of them and how their past VCYT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered VCYT in an article yet. Here's the latest on the wider market.
VCYT Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $15K – $50K | Jul 29, 2026 | Sep 22, 2026 | 55 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Mar 3, 2026 | Apr 7, 2026 | 35 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Feb 18, 2026 | Mar 10, 2026 | 20 d |
| Gilbert CisnerosD · CA | Sell (partial) | $1K – $15K | Nov 12, 2025 | Dec 15, 2025 | 33 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Jun 16, 2025 | Jul 10, 2025 | 24 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Veracyte
Veracyte is a diagnostic company based in South San Francisco, California. It develops and sells tests, many of them for cancer, that help physicians make decisions about patient care. Its best-known product is the Prosigna breast cancer test, which is available in international markets and runs on the nCounter Analysis System. The company also offers thyroid testing services and performs many of its tests in its own laboratories for physicians and healthcare providers.
- Headquarters
- South San Francisco, CA








